490 ARSENAL WAY, SUITE 200, WATERTOWN, MA
Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
Neumora Therapeutics Annual Meeting - Stockholder Votes on Proposals
Reports First Quarter 2026 Financial Results and Provides Business Update
Financial Results, Press Release
Investor Presentation
Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
Neumora Therapeutics Converts $2.5 Million Term Loan to Common Stock
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Certificate
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Automatic Shelf Registration Statement
Post-Effective Amendment to Registration Statement